We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Exiqon Launches LNA™ Gapmers

Read time: 1 minute

Exiqon A/S has announced the launch of its LNA™ longRNA GapmeR products for specific and efficient inhibition of mRNA and lncRNA.

The LNA™ longRNA GapmeRs are high affinity antisense oligonucleotides used for functional analysis, allowing researches to study the gene function and downstream biological consequences of silencing a specific mRNA or long non-coding RNA (lncRNA) in cell-cultures or animal models.

The broad range of LNA™ longRNA GapmeR products enables researcher to start from initial cost-effective in vitro screening in cell-lines of multiple gapmer designs and continue with high-purity animal-grade gapmers for in vivo testing.

The use of LNA™ enhanced antisense oligonucleotides in functional studies ensures superior performance and higher success rate through increased target accessibility, specificity, binding affinity, and tolerance.

In addition, the LNA™ longRNA GapmeRs enable easy unassisted (gymnotic) delivery into the cells resulting in broader applicability including hard-to-transfect cells lines.

By use of single-stranded RNase H-activating gapmer designs even targets in the nucleus can be addressed which may not be possible with alternative methods.

“We are thrilled to offer the LNA™ longRNA GapmeR products to our customers. The product line has already been tested by certain early access customer who clearly demonstrated the scientific potential of this product offering.” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.

All the LNA™ longRNA GapmerR are designed using Exiqon’s advanced and proprietary bioinformatics design algorithm which in combination with the LNA™ technology secure gapmers with excellent pharmacokinetic and pharmacodynamics properties including high stability and low toxicity for in vivo testing.

The incorporation of LNA™ increases the bio-stability which secures the biological activity over an extended period of time.

Exiqon offers a range of compatible LNA™ enhanced products for mRNA and lncRNA research including products for qPCR and in situ hybridization analysis.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.